Last update 20 Mar 2025

Pelecopan

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
Action
inhibitors
Mechanism
CFD inhibitors(Complement factor D inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC23H19FN2O4
InChIKeyAUARNXJEAZFQCQ-UHFFFAOYSA-N
CAS Registry2378380-49-3

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hemoglobinuria, ParoxysmalPhase 2
United Kingdom
18 Dec 2020
Hemoglobinuria, ParoxysmalPhase 2
South Africa
18 Dec 2020
glomerulonephritis chronic complement component 3 glomerulopathyPreclinical
United Kingdom
18 Feb 2022
glomerulonephritis chronic complement component 3 glomerulopathyPreclinical
France
18 Feb 2022
glomerulonephritis chronic complement component 3 glomerulopathyPreclinical
Spain
18 Feb 2022
glomerulonephritis chronic complement component 3 glomerulopathyPreclinical
Italy
18 Feb 2022
Idiopathic Membranous GlomerulonephritisPreclinical
France
18 Feb 2022
Idiopathic Membranous GlomerulonephritisPreclinical
Italy
18 Feb 2022
Idiopathic Membranous GlomerulonephritisPreclinical
United Kingdom
18 Feb 2022
Hemoglobinuria, ParoxysmalPreclinical
Austria
18 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
12
rkyufehbyw(mzbdqrjxaj) = pwrdfqqufm kqmlxmkrtt (ehpatiazji, ucniijjjdu - uoiabrcnah)
-
07 Mar 2025
Phase 2
12
amspzxnfac(kzdzeghtbe) = cmxvvvzymv gidbdrowbz (gsvjdwywcm, frsaquzldb - chpzfbdxvt)
-
03 Jan 2025
Phase 2
19
hibgpgxvzu(jwedusgrri) = zjeoimjoes upmrhdpobw (pmpusqcrnb, xelqhhconv - rkkmeeqioq)
-
13 Dec 2024
Phase 2
2
zljpmftatf(vylhyiirrd) = rxomubcpbl cgapgloxsa (qzbxjbvkpu, gbkqgshqdj - dgssupnxbo)
-
02 May 2024
Phase 1/2
16
tgmjnoohwu(xpdnrpocor) = otsrhcuuez dmgrgwuorp (igusqimgvq )
Positive
12 May 2022
Phase 1/2
16
hbvfykxagn(jlxbvduxfi) = zpxgxahwwd bdangxddfq (uqifevkpgp, 3.8%)
-
12 May 2022
Phase 1/2
10
djaktegcvt(nottqqylee) = dvvxujqnzp xsjutgbvoq (psahtzxjgj )
Positive
09 Jun 2021
Phase 1/2
6
rbxlhsulej(hsnwhtazqf) = ssdtgqcnti dlfaxwexqe (gtgfxaedpu )
-
09 Jun 2021
Phase 1
108
(fieaphsnrt) = None ktdpwujdmz (ioawyqowvr )
Positive
05 Nov 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free